John McCamant, editor of Medical Technology Stock Newsletter, Berkeley, California. Its model portfolio returned an annualized 31% over the past five years, compared with 14% for the S&P 500. BioInvest.com
Possible acquisitions could send stock prices of these three biotech companies soaring.
Read More >
The fact that President Donald Trump has called for lower drug prices, saying that the industry is “getting away with…
